Document Detail


Cisplatin-associated anaemia in patients with solid tumours. A retrospective evaluation and considerations relative to erythropoietin administration.
MedLine Citation:
PMID:  8739656     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have reviewed the incidence of cisplatin-induced anaemia in patients affected with solid tumours treated with at least three courses of first-line cisplatin-containing regimens. In our experience, a low percentage (5%) of patients required transfusions of red blood cells. We think it is of the utmost importance to adopt uniform criteria in monitoring and treatment of patients at risk of developing cisplatin anaemia and to identify subsets of patients to eventually treat with erythropoietin.
Authors:
M C Locatelli; L Tedeschi; M Clerici; A Romanelli; A D'Antona; R Labianca; G Luporini
Related Documents :
7381566 - Diagnosis of splenic involvement in hodgkin's disease by radionuclide evaluation of spl...
2182736 - Potential role of recombinant human erythropoietin in the peri-surgical setting.
7677966 - A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-gl...
11502666 - Plastic bronchitis and the role of bronchoscopy in the acute chest syndrome of sickle c...
7956396 - Decreased heart rate variability in patients with chronic obstructive pulmonary disease.
22613876 - Effect of continuous cerebrospinal fluid drainage on therapeutic intensity in severe tr...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer     Volume:  4     ISSN:  0941-4355     ISO Abbreviation:  Support Care Cancer     Publication Date:  1996 May 
Date Detail:
Created Date:  1996-10-10     Completed Date:  1996-10-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9302957     Medline TA:  Support Care Cancer     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  218-9     Citation Subset:  IM    
Affiliation:
Medical Oncology Department, S. Carlo Borromeo Hospital, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / chemically induced*,  drug therapy,  therapy
Antineoplastic Agents / administration & dosage,  adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use
Cisplatin / administration & dosage,  adverse effects*
Erythrocyte Transfusion
Erythropoietin / administration & dosage,  therapeutic use*
Evaluation Studies as Topic
Female
Humans
Incidence
Lung Neoplasms / drug therapy*
Male
Ovarian Neoplasms / drug therapy*
Prostatic Neoplasms / drug therapy*
Retrospective Studies
Risk Factors
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 11096-26-7/Erythropoietin; 15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Next Document:  A 5-year follow-up study of suicide attempts.